Publications by authors named "R R Radermecker"
Mild cognitive impairment, dementia and osteoporosis are common diseases of ageing and, with the increasingly ageing global population, are increasing in prevalence. These conditions are closely associated, with shared risk factors, common underlying biological mechanisms and potential direct causal pathways. In this review, the epidemiological and mechanistic links between mild cognitive impairment, dementia and skeletal health are explored.
View Article and Find Full Text PDFArticle Synopsis
- Finerenone is a targeted, non-steroidal drug that blocks the mineralocorticoid receptor and is effective in reducing heart and kidney disease complications in patients with type 2 diabetes and chronic kidney disease.
- Evidence from large clinical trials (FIDELIO-DKD and FIGARO-DKD) shows that it lowers the risk of cardiovascular issues and slows kidney disease progression.
- Additional studies are confirming its safety and efficacy in heart failure patients, and international guidelines recommend its use for high-risk individuals with type 2 diabetes.
Background: The use of interstitial glucose monitoring devices such as flash glucose monitoring has been shown to be beneficial in patients with type 1 diabetes mellitus (T1DM). However, these devices have been little studied in patients with diabetes treated by chronic haemodialysis (HD).
Methods: The goal of this prospective, observational, multicentric study was to evaluate the analytical performance of the FreeStyle Libre 2 (FSL2) sensor in T1DM patients during HD sessions.
This article reviews the use of continuous glucose monitoring (CGM) devices in the management of type 2 diabetes (T2D). Study results show that continuous CGM use improves glycemic control, lowers glycated hemoglobin (HbA1c) levels, and reduces hypoglycemic episodes compared with traditional monitoring methods. -Observational studies also suggest a reduction in diabetes-related emergencies and hospitalizations.
View Article and Find Full Text PDFArticle Synopsis
- Bone forming agents are important treatments for people with osteoporosis who have a very high risk of getting fractures.
- Doctors need to identify the right patients who will benefit the most from these treatments, especially those with severe osteoporosis or recent fractures.
- Using these agents can help strengthen bones and reduce fracture risk, and after treatment, patients should switch to other therapies to keep their bones strong.